Discussion Our meta-analysis demonstrated that semaglutide significantly reduced 23% in CV death, 18% in MACE, 22% in expanded MACE, 18% in nonfatal MI, and 32% in nonfatal stroke in patients with type 2 diabetes (T2D)
Kline AD, Moss JF, Selicorni A, Bisgaard AM, Deardorff MA, Gillett PM, et al
Customized medications tailored to your unique needs, offering personalized solutions for wellness, balance, and long-term health
A notable early mover Caregen, a major peptide company based in South Korea, has introduced a nutritional-grade bioactive peptide positioned as an anti-myostatin solution reported to carry a favorable safety profile and a relatively cost-effective price point
These insights include the understanding that signals from the gut to the brain suppress the appetite and help to control blood sugar levels
Semaglutide significantly improved RV function, as evidenced by reduced right ventricular systolic pressure (RVSP), hypertrophy index (RV/LV + S), and improved echocardiographic parameters (RVEDA, RVFAC, TAPSE)
